Loading clinical trials...

The Correlation Between HRD Detection and the Efficacy of PARP Inhibitors in Ovarian Cancer | Clinical Trials | Clareo Health

NOT_YET_RECRUITING

The Correlation Between HRD Detection and the Efficacy of PARP Inhibitors in Ovarian Cancer

The Correlation Between Homologous Recombination Deficiency Detection and the Efficacy of PARP Inhibitors in Ovarian Cancer

NCT06242392•Fujian Cancer Hospital

View on ClinicalTrials.gov

Summary

Clinicopathological data were collected from ovarian cancer patients treated with PARP inhibitors, with follow-up imaging conducted before and after treatment. The efficacy was evaluated according to RECIST criteria, comparing the correlation between different HRD statuses and the efficacy of PARP inhibitors in ovarian cancer.

Eligibility

Age

18 - No limit years

Sex

FEMALE

Healthy Volunteers

Inclusion Criteria

•Patients diagnosed with ovarian cancer (any histological type) and possessing complete pathological hematoxylin and eosin (HE) stained slides and paraffin-embedded tissue blocks.
•Patients must be 18 years of age or older.
•Patients should not have concurrent multiple primary cancers.
•Patients must undergo an MRI or CT scan prior to starting treatment.
•According to RECIST (Response Evaluation Criteria In Solid Tumors) criteria, patients must have at least one measurable lesion.
•Participants must provide informed consent, voluntarily cooperate with clinical follow-up, and sign an informed consent form.

Exclusion Criteria

•Patients who do not have accessible tumor tissue required for Homologous Recombination Deficiency (HRD) testing.
•Patients whose clinical records are incomplete, making it impossible to effectively compare treatment efficacy.
•Patients who are lost to follow-up and for whom subsequent treatment outcomes cannot be tracked.

Key Dates

Start Date

January 31, 2024

Primary Completion Date

May 1, 2026

Completion Date

July 1, 2026

Last Updated

February 5, 2024

Enrollment

250

ESTIMATED participants

Conditions

Ovarian Neoplasms

Interventions

homologous recombination deficiency

GENETIC

Contacts

Jian FC Chen

CONTACT

+8615806030009 marsz3@126.com

Yang Sun

CONTACT

15959028989 doctorsunyang@sina.com

A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer

NCT07213804

Ovarian NeoplasmsFallopian Tube Neoplasms+2 more

View study

RECRUITINGPHASE1/PHASE2

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

NCT06051695

Solid Tumor, AdultColorectal Cancer+18 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 5, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

The Correlation Between HRD Detection and the Efficacy of PARP Inhibitors in Ovarian Cancer

Inclusion Criteria

Exclusion Criteria

A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma

Diagnosis of Multiple Cancer and Monitoring of Minimal Residual Tumors After Treatment Using Blood and High-Sensitivity Genetic Analysis Techniques

Establishment of a Tumor Bank for Tissue Samples

Institut Paoli Calmettes Ovarian Cancer Database